ESTRO 2021 Abstract Book

S994

ESTRO 2021

Conclusion Based on clinical data, this work demonstrated PM as an independent predictor of lung SBRT outcomes, which can be used as a new tool for pre-treatment plan evaluation to improve patient prognosis.

PO-1198 Changes in radical radiotherapy for lung cancer patients in the UK during the COVID-19 pandemic. W. croxford 1 , K. Banfill 1 , I. Fornacon-Wood 2 , A. Britten 3 , C. Carson 4 , M. Hatton 5 , K. Thippu Jayaprakash 6 , A. Jegannathen 7 , P. Keng Koh 8 , N. Panakis 9 , C. Peedell 10 , A. Pope 11 , C. Powell 12 , C. Stilwell 13 , B. Thomas 14 , V. Wood 15 , S. Yun Zhou 16 , G. Price 2 , C. Faivre-Finn 1 1 The Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom; 2 University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom; 3 Royal Sussex County Hospital, Brighton and Sussex University Hospitals NHS Trust, Oncology, Brighton, United Kingdom; 4 Northern Ireland Cancer Centre, Oncology, Belfast, United Kingdom; 5 Weston Park Hospital, Oncology, Sheffield, United Kingdom; 6 Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Oncology, Cambridge, United Kingdom; 7 University Hospitals of North Midlands, Oncology, Stoke On Trent, United Kingdom; 8 New Cross Hospital, Oncology, Wolverhampton, United Kingdom; 9 Oxford University Hospitals, Oncology, Oxford, United Kingdom; 10 South Tees NHS Foundation Trust, Oncology, Middlesbrough, United Kingdom; 11 The Clatterbridge Cancer Centre NHS Foundation Trust, Oncology, Liverpool, United Kingdom; 12 Velindre Cancer Centre, Oncology, Cardiff, United Kingdom; 13 Aberdeen Royal Infirmary, Oncology, Aberdeen, United Kingdom; 14 Swansea Bay University Health Board, Oncology, Swansea, United Kingdom; 15 University Hospital Southampton NHS Foundation Trust, Oncology, Southampton, United Kingdom; 16 Beatson West of Scotland Cancer Centre, Oncology, Glasgow, United Kingdom Purpose or Objective Lung cancer patients are at high risk of developing severe COVID-19. Therefore, in response to the COVID-19 pandemic, guidelines were published in the UK (Faivre-Finn et al, 2020) to advise on reduced dose fractionation regimens for curative-intent radiotherapy (RT) for lung cancer. This reduces the frequency of hospital visits and thus potential exposure to SARS-CoV-2. We present the changes that occurred in the UK in this study (COVID-RT-Lung). Materials and Methods COVID-RT-Lung is a prospective multicentre UK data collection study. Inclusion criteria include: stage 1 – 3 lung cancer (biopsy-proven or diagnosed on cross-sectional imaging) referred for and/or treated with curative- intent RT between 2/4/2020 – 2/10/2020. Both patients who had a change in their management and those who continue with standard management are included. Data on demographics, COVID-19 diagnosis, diagnostic work-up, RT and systemic treatment, treatment-related toxicity, disease/patient status were collected. Each participating centre obtained local approval and anonymised data was collected on a central, cloud-based Research Electronic Data Capture system. Results 1352 patients from 28 UK sites were available for analysis on 25/01/2020. Median age 72 years (range 37 – 93), 675 (50.1%) male, and median PS 1 (range 0-3). 566 (42.1%) had stage 1 disease, 204 (15.2%) stage 2 and 574